Amicus Therapeutics, Inc. (FOLD)

Market Cap	2.76B
Revenue (ttm)	528.30M
Net Income (ttm)	-56.11M
Shares Out	300.12M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	466.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,534,263
Open	9.15
Previous Close	9.07
Day's Range	9.02 - 9.26
52-Week Range	8.79 - 14.02
Beta	0.61
Analysts	Strong Buy
Price Target	17.00 (+84.98%)
Earnings Date	Feb 19, 2025

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and Glaxo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 31, 2007
• Employees: 517
• Stock Exchange: NASDAQ
• Ticker Symbol: FOLD
• Website: https://amicusrx.com

Financial Performance

In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for FOLD stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 84.98% from the latest price.

Price Target

$17.0

(84.98% upside)

Analyst Consensus: Strong Buy